IP Library Granted Patent US 12,458,652
Granted Patent B2
US 12,458,652 · App. 17/984,405 · Granted Nov 4, 2025

Pharmaceutical compositions of spironolactone for deep dermal drug delivery

Inventors: David W. Osborne (Fort Collins, CO); Babak N. Tofig (Westlake Village, CA)
Assignee: ARCUTIS BIOTHERAPEUTICS, INC.
A61K31/585A61K9/0014A61K9/009A61K9/107A61K9/122A61K47/20A61K47/38
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,458,652
App. No.
17/984,405
Granted
Nov 4, 2025
Kind
B2
Abstract

Pharmaceutical compositions for the topical administration of spironolactone to the pilosebaceous unit and methods for administering the same. The pharmaceutical compositions comprise aqueous suspensions of submicron particles of spironolactone in water.

Claims (24)

1 . A topical pharmaceutical composition comprising:

a therapeutically effective amount of about 0.10% w/w to about 7.5% w/w of spironolactone or a pharmaceutically acceptable salt thereof, wherein a primary particle size distribution of the spironolactone is characterized by a D90 value of less than about 0.25 μm; and

water,

wherein the spironolactone is suspended in water.

2 . The pharmaceutical composition of claim 1 , wherein the composition further comprises dioctyl sodium sulfosuccinate.

3 . The pharmaceutical composition of claim 2 , wherein the composition further comprises hydroxyl propyl cellulose.

4 . A package comprising the pharmaceutical composition of claim 1 , wherein the package is selected from the group consisting of a sachet comprising a towelette or wipe, a pump comprising a spray or foam, a control flow applicator comprising a sponge, or a dropper or dropper bottle comprising a suspension.

5 . The method of claim 1 , wherein the composition does not comprise a preservative.

6 . A topical pharmaceutical composition consisting essentially of:

a therapeutically effective amount of about 0.10% w/w to about 7.5% w/w of spironolactone or a pharmaceutically acceptable salt thereof, wherein a primary particle size distribution of the spironolactone is characterized by a D90 value of less than about 0.25 μm;

dioctyl sodium sulfosuccinate;

hydroxyl propyl cellulose; and

water,

wherein the spironolactone is suspended in water.

7 . The pharmaceutical composition of claim 6 , wherein the composition comprises about 0.01% w/w to about 1% w/w of dioctyl sodium sulfosuccinate; and about 0.01% to about 1.5% w/w of hydroxyl propyl cellulose.

8 . A package comprising the pharmaceutical composition of claim 6 , wherein the package is selected from the group consisting of a sachet comprising a towelette or wipe, a pump comprising a spray or foam, a control flow applicator comprising a sponge, or a dropper or dropper bottle comprising a suspension.

9 . The method of claim 6 , wherein the composition does not comprise a preservative.

10 . A method of treating a hair or skin condition in a subject in need thereof comprising:

topically administering to the subject a pharmaceutical composition comprising: (a) a therapeutically effective amount of about 0.10% w/w to about 7.5% w/w of spironolactone or a pharmaceutically acceptable salt thereof, wherein a primary particle size distribution of the spironolactone is characterized by a D90 value of less than about 0.25 um; and (b) water, and

wherein the hair or skin condition is selected from the group consisting of acne, alopecia areata, or male pattern baldness,

wherein the spironolactone is suspended in water.

11 . The method of claim 10 , wherein the composition further comprises dioctyl sodium sulfosuccinate.

12 . The method of claim 11 , wherein the composition further comprises hydroxyl propyl cellulose.

13 . The method of claim 10 , wherein the composition does not comprise a preservative.

Assignments (2)
SECURITY INTEREST Recorded Aug 9, 2024
From: ARCUTIS BIOTHERAPEUTICS, INC.
To: SLR INVESTMENT CORP.
Reel/Frame 068236/0418 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2023
From: OSBORNE, DAVID W.; TOFIG, BABAK N.
To: ARCUTIS BIOTHERAPEUTICS, INC.
Reel/Frame 064637/0365 →
Continuity (2)
Provisional Application 63278377 · Nov 11, 2021
Related Publication 20230143609A1 · May 11, 2023
References Cited (43)
US 8003690B2 · Vergnault · 2011 [cited by examiner]
US 9114077B2 · Petersen · 2015 [cited by applicant]
US 9422300B2 · Sun et al. · 2016 [cited by applicant]
US 9527851B2 · Zhang et al. · 2016 [cited by applicant]
US 9636353B2 · Mittal et al. · 2017 [cited by applicant]
US 9713590B2 · Mittal et al. · 2017 [cited by applicant]
US 9757394B2 · Pipho · 2017 [cited by examiner]
US 10023577B2 · Sun et al. · 2018 [cited by applicant]
US 10150770B2 · Sun et al. · 2018 [cited by applicant]
US 10428074B2 · Zhang et al. · 2019 [cited by applicant]
US 10786507B2 · Lu et al. · 2020 [cited by applicant]
US 20060159638A1 · Segura et al. · 2006 [cited by applicant]
US 20130072512A1 · Jahagirdar et al. · 2013 [cited by applicant]
US 20160279152A1 · Chen et al. · 2016 [cited by applicant]
US 20160361381A1 · Green et al. · 2016 [cited by applicant]
US 20170020896A1 · Kelidari · 2017 [cited by examiner]
US 20170044171A1 · Zhang et al. · 2017 [cited by applicant]
US 20190060311A1 · Shanler et al. · 2019 [cited by applicant]
US 20200276109A1 · Xi et al. · 2020 [cited by applicant]
CN 111278466A · 2020 [cited by applicant]
EP 0479777A1 · 1992 [cited by applicant]
EP 3714887A1 · 2020 [cited by applicant]
WO 9011077A1 · 1990 [cited by applicant]
WO 2019040706A1 · 2019 [cited by applicant]
WO 2019236596A1 · 2019 [cited by applicant]
WO 2022108913A1 · 2022 [cited by applicant]
Ferreira-Nunes et al. Follicular-targeted delivery of spironolactone provided by polymeric nanoparticles. Colloids and Surfaces B: Biointerfaces. Sep. 2021. 208:112101 (Year: 2021). [cited by examiner]
Noaimi et al. Treatment of Acne Vulgaris by Topical Spironolactone Solution Compared With Clindamycin Solution. Aug. 31, 2021. Cureus. 13(8): e17606 (Year: 2021). [cited by examiner]
Noaimi et al. (Cureus. 13(8): e17606 (Aug. 31, 2021) (Year: 2021). [cited by examiner]
International Search Report and the Written Opinion of the International Searching Authority, issued in corresponding International Application No. PCT/US2021/059487, dated Mar. 4, 2022, 14 pages. [cited by applicant]
International Search Report and the Written Opinion of the International Searching Authority, issued in corresponding International Application No. PCT/US2021/059479, dated Mar. 11, 2022, 18 pages. [cited by applicant]
MinoxidilMax, “Topical Spironolactone 5% for Hair Loss, Acne,” printed on Feb. 22, 2022, X055894342, retrieved from the Internet: https://www.minoxidilmax.com/topical-spironolactone, 6 pages. [cited by applicant]
Leite-Silva et al. “The Influence of Emollients on Dermal and Transdermal Drug Delivery” In Percutaneous Penetration Ehancers Drug penetration Into/Through the Skin Methodology and General Considerations, May 4, 2017 (M… [cited by applicant]
“Cyclomethicone/Dimethicone,” Handbook of Pharmaceutical Excipients, Fifth Edition, Jan. 1, 2006 (Jan. 1, 2006), Pharmaceutical Press, XP055889869, 6 pages. [cited by applicant]
Wu Ke et al., “Quality Assessment of API in Semisolid Topical Drug Products,” The Role of Microstructure in Topical Drug Product Development, Aug. 7, 2019 (Aug. 7, 2019), Springer International Publishing, XP055895570, … [cited by applicant]
Annika Vogt et al., “Follicular Targeting—A Promising Tool in Selective Dermatotherapy,” JID Symposium Proceedings, (2005), 10(3):252-255. [cited by applicant]
D. W. Osborne et al., “The Influence of Skin Surface Lipids on Topical Formulations,” Marcel Dekker, New York (1990), pp. 69-86. [cited by applicant]
Andrea C. Lauer et al., “Transfollicular Drug Delivery”, Pharmaceutical Research, (1995), 12(2):179-186. [cited by applicant]
Amit Verma et al., “Transfollicular drug delivery: current perspectives,” Research and Reports in Transdermal Drug Delivery, (2016), 5:1-17. [cited by applicant]
Attwa et al., “Efficacy and safety of topical spironolactone 5% gel versus placebo in the treatment of acne vulgaris,” Egyptian J. Dermatol. Venerol., (2019), 39:89-94. [cited by applicant]
J.W. Charny et al., “Spironolactone for the treatment of acne in women, a retrospective study of 110 patients,” Int. J. Womens Dermatol., (2017), 3(2): 111-115. [cited by applicant]
Harvey et al., MALDI-MSI for the Analysis of a 3D Tissue-Engineered Psoriatic Skin Model, Proteomics 2016 (2016), 16, 1718-1725. [cited by applicant]
International Search Report and the Written Opinion of the International Searching Authority, issued in corresponding International Application No. PCT/US2022/049545, dated Mar. 6, 2023, 13 pages. [cited by applicant]